Literature DB >> 8945728

Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease.

G Stypuła1, J Kunert-Radek, H Stepień, K Zylińska, M Pawlikowski.   

Abstract

Parkinson's disease (PD) is characterized by a markedly decreased number of nigrostriatal dopaminergic neurons. The pathogenesis of PD is still unknown; among other etiological factors, immunological abnormalities have been suggested. Recently, interleukin-2 (IL-2) has been hypothesized to be an endogenous cytokine that regulates striatal dopaminergic function. We examined the plasma concentrations of IL-1, IL-2, IL-6 and blood levels of ACTH, cortisol and prolactin of 21 patients with PD without any previous treatment. Age- and sex-matched subjects without any neurological or immune disorders were used as controls. Significantly higher serum concentrations of IL-2 in patients with PD were found. Treatment with antiparkinsonian drugs reduced IL-2 levels in these patients. Our results suggested a functional relationship between central dopaminergic and immune systems and a possible involvement of the latter in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8945728     DOI: 10.1159/000097237

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  32 in total

1.  Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.

Authors:  Chi Wang Ip; Sandra K Beck; Jens Volkmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-20       Impact factor: 3.575

2.  Interleukin-6 serum levels in patients with Parkinson's disease.

Authors:  Kerly Wollmeister Hofmann; Artur Francisco Schumacher Schuh; Jonas Saute; Raquel Townsend; Daniele Fricke; Renata Leke; Diogo O Souza; Luis Valmor Portela; Márcia Lorena Fagundes Chaves; Carlos R M Rieder
Journal:  Neurochem Res       Date:  2009-02-13       Impact factor: 3.996

3.  Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  D P Ferrari; M Bortolanza; E A Del Bel
Journal:  Neurotox Res       Date:  2021-03-09       Impact factor: 3.911

4.  Markers of inflammation in prevalent and incident Parkinson's disease in the Cardiovascular Health Study.

Authors:  Thanh G N Ton; Samay Jain; Mary L Biggs; Evan L Thacker; Elsa S Strotmeyer; Robert Boudreau; Anne B Newman; W T Longstreth; Harvey Checkoway
Journal:  Parkinsonism Relat Disord       Date:  2011-11-26       Impact factor: 4.891

Review 5.  [New therapy approaches for Parkinson's disease].

Authors:  K Brockmann; D Berg
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

Review 6.  Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases.

Authors:  M Reale; N H Greig; M A Kamal
Journal:  Mini Rev Med Chem       Date:  2009-09       Impact factor: 3.862

Review 7.  Parkinson's disease and inflammatory changes.

Authors:  Carlos Barcia; Andrés Fernández Barreiro; Máximo Poza; María-Trinidad Herrero
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  The Anti-inflammatory Effects of 4-((5-Bromo-3-chloro-2-hydroxybenzyl) amino)-2-hydroxybenzoic Acid in Lipopolysaccharide-Activated Primary Microglial Cells.

Authors:  Xiang Cao; Yuexinzi Jin; He Zhang; Linjie Yu; Xinyu Bao; Fei Li; Yun Xu
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

9.  Cortisol levels, motor, cognitive and behavioral symptoms in Parkinson's disease: a systematic review.

Authors:  Nayron Medeiros Soares; Gabriela Magalhães Pereira; Vivian Altmann; Rosa Maria Martins de Almeida; Carlos R M Rieder
Journal:  J Neural Transm (Vienna)       Date:  2018-10-29       Impact factor: 3.575

10.  Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease.

Authors:  Isabelle St-Amour; Mélanie Bousquet; Isabelle Paré; Janelle Drouin-Ouellet; Francesca Cicchetti; Renée Bazin; Frédéric Calon
Journal:  J Neuroinflammation       Date:  2012-10-09       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.